Zacks: Brokerages Anticipate Anixa Biosciences, Inc. (NASDAQ:ANIX) Will Announce Earnings of -$0.11 Per Share

Equities research analysts predict that Anixa Biosciences, Inc. (NASDAQ:ANIX) will announce earnings of ($0.11) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Anixa Biosciences’ earnings. Anixa Biosciences reported earnings per share of ($0.13) in the same quarter last year, which suggests a positive year-over-year growth rate of 15.4%. The business is expected to announce its next quarterly earnings report on Monday, March 8th.

On average, analysts expect that Anixa Biosciences will report full year earnings of ($0.51) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.49). For the next financial year, analysts anticipate that the firm will post earnings of ($0.60) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Anixa Biosciences.

A number of brokerages have weighed in on ANIX. Aegis restated a “buy” rating on shares of Anixa Biosciences in a report on Monday, February 15th. Zacks Investment Research lowered Anixa Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, January 14th.

ANIX stock traded down $0.33 during midday trading on Tuesday, reaching $4.60. The stock had a trading volume of 8,985 shares, compared to its average volume of 395,993. The company’s fifty day simple moving average is $4.40 and its 200 day simple moving average is $2.99. The company has a market cap of $119.95 million, a price-to-earnings ratio of -10.00 and a beta of 1.58. Anixa Biosciences has a 52-week low of $1.33 and a 52-week high of $5.63.

In other Anixa Biosciences news, CEO Amit Kumar bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, January 29th. The stock was purchased at an average price of $3.73 per share, for a total transaction of $37,300.00. Following the completion of the purchase, the chief executive officer now directly owns 272,000 shares in the company, valued at $1,014,560. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 23.30% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Anixa Biosciences by 8.0% in the fourth quarter. BlackRock Inc. now owns 93,942 shares of the company’s stock valued at $289,000 after purchasing an additional 6,964 shares during the period. B. Riley Wealth Management Inc. acquired a new position in Anixa Biosciences during the fourth quarter worth $37,000. Bank of New York Mellon Corp grew its holdings in Anixa Biosciences by 32.0% in the fourth quarter. Bank of New York Mellon Corp now owns 51,969 shares of the company’s stock valued at $160,000 after purchasing an additional 12,588 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Anixa Biosciences in the third quarter valued at $45,000. 7.68% of the stock is currently owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus.

Recommended Story: What are different types of coverage ratios?

Get a free copy of the Zacks research report on Anixa Biosciences (ANIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com